Guardant Health AMEA

Overview

Guardant Health AMEA is a precision oncology company focused on improving cancer care globally. It utilizes proprietary blood and tissue tests, extensive data sets, and advanced analytics, including AI, to enhance patient outcomes across all stages of cancer treatment. The company offers non-invasive liquid biopsy tests that help in early cancer screening, monitoring for recurrence, and guiding treatment decisions for advanced cancer patients.

As a regional arm of Guardant Health, Inc., it aims to address the rising cancer burden in Asia, the Middle East, and Africa. Operating in more than 60 countries, the company provides access to innovative liquid biopsy technologies such as the Guardant Complete® test for treatment guidance and the Shield test for early colorectal cancer detection, collaborating with healthcare providers, laboratories, and pharmaceutical companies to advance cancer therapies and improve patient care.

Basic Information

Contact Details

• Phone: +1 855-698-8887
• Website: guardanthealthamea.com
• LinkedIn: linkedin.com/company/guardanthealthamea

Key Focus Areas & Initiatives

• Health & wellness
• Biotechnology research
• Clinical trials support
• Early cancer detection
• Epigenomic analysis in cancer
• Guardant360 response
• Cancer therapy personalization
• Cancer biomarker detection
• Tumor mutation profiling
• Global cancer diagnostics
• Cancer research tools
• Multiomic analysis
• Early cancer screening
• Minimal residual disease
• Liquid biopsy in clinical trials
• Laboratory testing
• Tumor heterogeneity assessment
• Cancer management
• Oncology diagnostics
• Cancer monitoring
• Blood tests
• Cancer detection technology
• Oncology research tools
• Guardant reveal
• Guardant360 cdx
• Personalized cancer therapy
• Cancer diagnostics
• Liquid biopsy
• Treatment response monitoring
• Cancer patient outcomes
• Diagnostic accuracy
• Regulatory approval
• Cancer treatment monitoring
• Next-generation sequencing
• Treatment guidance
• Pharma partnerships
• Tissue biopsy alternatives
• Genomic and epigenomic insights
• Molecular insights
• B2B
• Cancer detection
• Non-invasive tumor profiling
• Personalized medicine
• Cancer biomarker testing
• Cancer progression tracking
• Multiomic profiling
• Cancer treatment optimization
• Biopharma solutions
• Liquid biopsy for solid tumors
• Precision medicine tools
• Pharmaceuticals
• Cancer therapy selection
• Genomic profiling
• Cancer genomics research
• Biomarker-guided therapy
• Molecular profiling
• Biopharma collaboration
• Data-driven insights
• Personalized oncology
• Cancer treatment guidance
• Cancer care solutions
• Genomic insights
• Cancer treatment
• Treatment response assessment
• Tumor DNA
• Cancer recurrence detection
• Liquid biopsy panels
• Epigenomic insights
• Guardant360 tissue
• Liquid biopsy technology
• Government
• Cancer genomics
• Molecular tumor profiling
• Non-invasive blood test
• Research and development in the physical, engineering, and life sciences
• Cancer evolution tracking
• Comprehensive genomic profiling
• Tumor DNA detection
• Clinical decision support tools
• Cancer care innovation
• Biotechnology
• Medical diagnostics
• Oncology drug development
• Cancer evolution monitoring
• Recurrence monitoring
• Tumor profiling
• AI analytics
• Clinical decision support
• ctDNA detection
• Diagnostic services
• Precision oncology diagnostics
• Cancer treatment response
• Clinical data
• Cancer screening tests
• Molecular diagnostics
• Cancer biomarker discovery
• Oncology research
• Circulating tumor DNA
• Healthcare
• Cancer diagnostics platform
• Non-invasive testing
• Guardant360 liquid
• Minimal residual disease detection
• Cancer patient management
• Precision oncology
• Epigenomics
• Services
• Cancer recurrence management
• Real-world data
• Cancer biomarker analysis
• Biomarker analysis
• Biomarker discovery
• Cancer progression monitoring
• Cancer screening
• Consulting
• Recurrence detection
• Blood test
• Minimally invasive testing
• Targeted therapy
• Clinical trials
• Companion diagnostics
• Colorectal cancer screening
• Solid tumor testing
• Patient outcomes
• Molecular response assessment
• Tissue biopsy
• Guardant complete portfolio
• Shield blood test
• Treatment selection
• Cancer care continuum
• Biomarker detection
• Tissue-free biopsy
• ctDNA analysis
• Advanced cancer testing
• Clinical diagnostics
• Cancer therapy development
• Treatment efficacy monitoring
• Patient-centric solutions
• Clinical pathway optimization
• Biopharmaceutical collaboration
• Healthcare innovation
• Data analytics for oncology
• Companion diagnostics for cancer
• Distribution
• Health, wellness & fitness
• Medical
• Health care
• Hospital & health care

Technologies Used

• AI
• Adobe Media Optimizer
• Amazon AWS
• Apache
• Atlassian Cloud
• BugHerd
• Cedexis Radar
• DigitalOcean
• Drupal
• Facebook Conversion Tracking
• Facebook Custom Audiences
• Facebook Login (Connect)
• Facebook Widget
• Google Analytics
• Google Font API
• Google Maps
• Google Places
• Google Tag Manager
• Gravity Forms
• JQuery 2.1.1
• Linkedin Marketing Solutions
• Mobile Friendly
• Oracle Cloud
• Outlook
• React
• React Redux
• Remote
• Route 53
• SmartRecruiters
• Twitter Advertising
• Vimeo
• WordPress.org
• YouTube
• reCAPTCHA

Affiliated Organizations & Regional Branches

• Bellwether Bio